Land: USA
Språk: engelska
Källa: NLM (National Library of Medicine)
VALBENAZINE TOSYLATE (UNII: 5SML1T733B) (VALBENAZINE - UNII:54K37P50KH)
Neurocrine Biosciences, Inc.
VALBENAZINE
VALBENAZINE 40 mg
ORAL
PRESCRIPTION DRUG
INGREZZA is indicated for the treatment of adults with: - tardive dyskinesia [see Clinical Studies ( 14.1 )] . - chorea associated with Huntington’s disease [see Clinical Studies ( 14.2 )] . INGREZZA is contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA. Rash, urticaria, and reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth) have been reported [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.2 )]. Risk Summary The limited available data on INGREZZA use in pregnant women are insufficient to inform a drug-associated risk. In animal reproductive studies, no malformations were observed when valbenazine was administered orally to rats and rabbits during the period of organogenesis at doses up to 1.8 or 24 times, respectively, the maximum recommended human dose (MRHD) of 80 mg/day based on mg/m2 body surface area. However, administration of valbenazine to pregnant rats during organogenesis through lactation p
INGREZZA (valbenazine) capsules are available as: 40 mg Capsule: White opaque body with a purple cap, printed with ‘VBZ’ and ‘40’ in black ink. 60 mg Capsule: Dark red opaque body with a purple cap, printed with ‘VBZ’ and ‘60’ in black ink. 80 mg Capsule: Purple opaque body and cap, printed with ‘VBZ’ and ‘80’ in black ink. Storage Store at 15°C to 30°C (59°F to 86°F).
New Drug Application
INGREZZA- VALBENAZINE CAPSULE INGREZZA- VALBENAZINE NEUROCRINE BIOSCIENCES, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE INGREZZA SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR INGREZZA. INGREZZA (VALBENAZINE) CAPSULES, FOR ORAL USE INITIAL U.S. APPROVAL: 2017 WARNING: DEPRESSION AND SUICIDAL IDEATION AND BEHAVIOR IN PATIENTS WITH HUNTINGTON’S DISEASE _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ • INCREASES THE RISK OF DEPRESSION AND SUICIDAL THOUGHTS AND BEHAVIOR IN PATIENTS WITH HUNTINGTON’S DISEASE (5.1) • BALANCE RISKS OF DEPRESSION, AND SUICIDAL IDEATION AND BEHAVIOR WITH THE CLINICAL NEED FOR TREATMENT OF CHOREA WHEN CONSIDERING THE USE OF INGREZZA (5.1) • MONITOR PATIENTS FOR THE EMERGENCE OR WORSENING OF DEPRESSION, SUICIDAL IDEATION, OR UNUSUAL CHANGES IN BEHAVIOR (5.1) • INFORM PATIENTS, CAREGIVERS, AND FAMILIES OF THE RISK OF DEPRESSION AND SUICIDAL IDEATION AND BEHAVIOR AND INSTRUCT THEM TO REPORT BEHAVIORS OF CONCERN PROMPTLY TO THE TREATING PHYSICIAN (5.1) • EXERCISE CAUTION WHEN TREATING PATIENTS WITH A HISTORY OF DEPRESSION OR PRIOR SUICIDE ATTEMPTS OR IDEATION (5.1) RECENT MAJOR CHANGES Boxed Warning 8/2023 Indications and Usage (1) 8/2023 Dosage and Administration (2.1) 8/2023 Warnings and Precautions (5.1, 5.2, 5.5, 5.6) 8/2023 INDICATIONS AND USAGE INGREZZA is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with: - tardive dyskinesia. (1) - chorea associated with Huntington’s disease. (1) DOSAGE AND ADMINISTRATION Tardive dyskinesia: The initial dosage is 40 mg once daily. After one week, increase the dose to the recommended dosage of 80 mg once daily. (2.1) Chorea associated with Huntington’s disease: The initial dosage is 40 mg once daily. Increase the dose in 20 mg increments every two weeks to the recommended dosage of 80 mg once daily. (2.1) 40 mg or 60 mg once daily may be considered depending on response and tolerability Läs hela dokumentet